The Hybrid International Conference on Tumor Immunology and Immunotherapy, organized by the International Research Conference, will take place on May 24-25, 2025, in New York, USA. This conference aims to facilitate the exchange of experiences and research results among leading academic scientists, researchers, and research scholars in the fields of Tumor Immunology and Immunotherapy. It provides a premier interdisciplinary platform for presenting the latest innovations, trends, and concerns in these areas. The conference program will feature diverse scholarly events scheduled throughout the conference duration, offering valuable insights for students, academics, and industry researchers. Attendees can expect high-quality presentations and discussions addressing practical challenges and innovative solutions in Tumor Immunology and Immunotherapy.

Read on waset.org

Vaccines & Immunotherapies Online Symposium will be held on 26 September 2024.The program features case studies in vaccine development for cancer and infectious diseases, offering insights into best practices and technological advancements. Engage in focused discussions and networking with thought leaders to understand immunotherapy innovations for cancer and autoimmune diseases. The event concludes with the release of the ‘Harnessing Vaccine Technologies & Immunotherapies with Best Practice Approaches’ report, summarizing key insights and emerging trends.

 [Read on oxfordglobal](https://oxfordglobal.com/biologics/events/vaccines-immunotherapies-online-symposium)

The 4th International Conference on Lymphocyte Engineering (ICLE 2023) will take place on 12-14 September 2023 in Munich, Germany.

ICLE is a cornerstone conference for the latest advances in immune-gene therapy, where ground-breaking research in the field is presented along with innovative clinical practices and treatment. Join the 2023 edition as it brings together immunotherapy with cell and gene therapy to foster interdisciplinary collaborations, deepening the connection between basic and clinical research across related disease specialties.

ICLE 2023 will once again take place in Munich - home to the biggest European research hub in the field, the perfect location for the only international conference focusing specifically on research and clinical translation of gene therapy, cell therapy, genome engineering, and immunotherapy.

Great strides have been made in recent years in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, pathogenic diseases, and primary immune deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging field of lymphocyte engineering employs cutting-edge technologies of viral and non-viral vectorology, genome editing, and protein design as well as advanced clinical protocols for cell harvest, expansion, and re-infusion and for the exciting alternative of in vivo engineering. With groundbreaking clinical success leading to FDA-approved products and with vibrant, exponentially growing research, lymphocyte engineering is the wave of the future.

Still, the challenges are formidable, and the stakes are high. Realizing the full promise of lymphocyte engineering will require the combined efforts of a dedicated community. ICLE 2023 will facilitate the sharing of data and ideas, promote collaborations, and address common challenges to advance clinical translation. It will provide an effective environment for active learning, discussions of real-world case studies, and networking between like-minded peers. Learn what is done to translate the lymphocyte engineering research to clinical practice and how your colleagues overcome their challenges. Hear from renown leaders, sharing invaluable insights on lymphocyte engineering therapies and discuss the latest findings and trends.

Whether you are a scientist, clinical researcher, part of a start-up, or an established industry company, ICLE 2023 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality.

Read on kenes.com